SVRA

Savara Inc

$6.22 +0.16 (+2.64%) At close · Jul 2

Market Cap

$1.27B

204,927,212

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date	Headline
2026-06-12	Savara Announces New Employment Inducement Grant
2026-06-08	Savara Announces Chief Financial and Administrative Officer Transition
2026-05-27	Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
2026-05-20	Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
2026-05-19	Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
2026-05-18	Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
2026-05-12	Savara Reports First Quarter Financial Results and Provides Business Update
2026-05-11	Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
2026-04-17	Savara Announces New Employment Inducement Grant
2026-04-15	Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Past events

Date	Event	Type
2026-06-03	Jefferies Global Healthcare Conference	Conference
2026-05-19	H.C. Wainwright 4th Annual BioConnect Investor Conference	Conference

Source: https://investors.savarapharma.com/overview/default.aspx

Key facts CIK 1160308 CUSIP 805111101 Visit website Investor relations